Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients
The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes.
We will perform an observational study where we follow up patients with uncontrolled type 2 Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6 months in the diabetic clinic. Our hypothesis is that glucose control will improve the response to aspirin in those patients.
|Diabetes Mellitus, Type II|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients|
- The outcome measure is the laboratory Aspirin Resistance. [ Time Frame: 3 and 6 months. ]
- To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors. [ Time Frame: On screening visit. ]
|Study Start Date:||November 2008|
|Study Completion Date:||November 2010|
|Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00649909
|Hadassah Medical Organization|
|Principal Investigator:||David Varon, MD||Hematology Department, Hadassah Medical Organization, Jerusalem, Israel|